摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed is a pharmaceutical composition for peroral introduction for treatment of malignant tumours in a patient, excluding non-Hodgkin's lymphoma, myelodysplastic syndrome, leukemia and malignant tumours with leukocyte infiltration, which contains up to 400 mg of the solid drug form of suberoylanilide hydroxamic acid (SAHA), or its pharmaceutically acceptable salt, or a hydrate.EFFECT: solid drug form of SAHA, which has a crystalline structure was characterised by stability and provided partial reaction of a malignant tumour of the larynx with metastases or shrinkage of the solid tumour by results of CT-scanning.22 cl, 12 dwg, 7 tbl |